Theranexus SA (DE:3VG)
FRANKFURT:3VG
Want to see DE:3VG full AI Analyst Report?
3VG Stock Chart & Stats
€2.74
-€0.06(-8.12%)
At close: 4:00 PM EST
€2.74
-€0.06(-8.12%)
Day’s Range― - ―
52-Week Range€0.70 - €4.31
Previous CloseN/A
Volume0.00
Average Volume (3M)596.00
Market Cap
€48.58M
Enterprise Value€34.12M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume242
30 Day Avg. Volume596
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnership-driven DevelopmentTheranexus' model of advancing clinical-stage programs while leveraging partnerships reduces capital intensity and shares development risk. For a small biotech, durable partner relationships can provide expertise, non-dilutive resources or co-development paths that increase the odds of progressing assets over the medium term.
Improving Cash-burn TrendReported improvement in cash burn magnitude in 2024–2025 versus 2023 indicates better cost control and operational discipline. Sustained lower burn extends runway, reduces near-term financing pressure, and gives the company more time to reach clinical inflection points without immediate dilutive raises.
Reduced Debt & Equity RecoveryDebt around €2.9m with equity returning to positive in 2025 shows a structural improvement versus prior distress. Lower leverage and restored equity increase solvency and financial flexibility, improving the firm's ability to fund R&D or negotiate partnerships on more favorable terms over the medium term.
Bears Say
Persistent UnprofitabilityTheranexus is loss-making across reported periods with negative gross profit and deeply negative operating results. Chronic unprofitability steadily erodes capitalization, forces recurrent external funding, limits reinvestment capacity, and creates a durable risk to long-term viability absent a clear path to sustained revenues.
Revenue Collapse & InstabilityRevenue volatility culminating in zero reported revenue in 2025 undermines predictability of cash inflows and operational planning. Such swings suggest execution, commercialization or contract risks that materially increase financing and execution risk for the business over the medium term.
Reliance On External FinancingThe firm's dependence on external financing amid asset declines and past negative equity creates persistent dilution and funding-risk exposure. Reliance on capital markets or partners ties R&D progress to market conditions and deal flow, a structural vulnerability for sustaining clinical development.
Theranexus SA News
3VG FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €0.70 and its highest was €4.31 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €48.58M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is Sep 24, 2026 which is in 125 days.
How were Theranexus SA’s earnings last quarter?
Currently, no data Available
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in DE:3VG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Technical Analysis
Options Prices
Currently, No data available
---